Advance | $8,550,000 | (Feb 6, 2026)
Turnstile | $29,000,000 | (Feb 6, 2026)
Accrual | $75,000,000 | (Feb 6, 2026)
Renasant Bio
United States
- Berkeley, California
- 11/07/2025
- Seed
- $54,500,000
Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression.
- Industry Biotechnology Research
- Website https://www.renasantbio.com/
- LinkedIn https://www.linkedin.com/company/renasant-bio/
Related People
Emily ConleyFounder
United States -
San Francisco Bay Area
Strategic biotech executive with a proven track record of advancing disruptive platforms in drug
development. Architect of visionary partnerships across pharma and biotech (big cap to small cap).
Expert at scaling: joined 23andMe at 30 employees and helped grow it to 600+. Deep scientific
expertise with 35 academic publications. Industry thought-leader with national TV appearances.
Named one of the “20 under 40” leaders in biotech. Multiple board appointments. Big-picture thinker,
who is passionate about healthcare with a gift for inspiring teams and helping companies thrive.
Connect Music | $80,000,000 | (Feb 6, 2026)
adaption | $50,000,000 | (Feb 6, 2026)
Cadastral | $9,500,000 | (Feb 6, 2026)
Nixtla | $16,000,000 | (Feb 6, 2026)
Nullify | $12,500,000 | (Feb 6, 2026)
Uplift360 | $8,724,008 | (Feb 6, 2026)
Fundamental | $255,000,000 | (Feb 6, 2026)
Duna | $35,365,500 | (Feb 6, 2026)